The Lancer Group places Albert Garcia as Chief Operating Officer of BioMatrix, a nationally recognized specialty pharmacy company
WESTON, FL – The Lancer Group places Albert Garcia as Chief Operating Officer of BioMatrix, a leading specialty pharmacy network that caters to patients with blood disorders, organ transplants, and other chronic and acute diseases and conditions. BioMatrix is backed by leading Private Equity firm, ACON Investments.
Albert brings to BioMatrix over 30 years of experience driving top sales growth, profit improvement and shareholder value across the retail multisite space. In this new role, Albert will grow and optimize the company’s operations in addition to leading and integrating strategic M&A. He will be responsible for working with key drug development relationships for new therapies as well as designing and investing in core functions of the company including pharmacy operations, service delivery & service innovation, operational effectiveness and sales & marketing.
Most recently, Albert served as President & General Manager of Coram CVS, one of the nation’s largest specialty infusion services provider, where he led process improvement and operational centralization leading to improvements in productivity. Prior to joining Coram CVS, Albert spent over a decade at Navarro Discount Pharmacy, the largest Hispanic retail pharmacy, where he oversaw all operations, fulfilment and wholesale distribution centers.
He holds a Master’s degree in Health Law from Nova Southeastern University and aBachelor’s in Pharmacy from the University of Florida.
About The Lancer Group
The Lancer Group is a leading retained executive search firm that is trusted by private equity firms, their portfolio companies and public corporations to deliver high-impact leaders. The firm specializes in board-driven search mandates including CEOs, CFOs, C-suite executives and board directors as well as private equity investment professionals and operating partners. The Lancer Group has provided strategic counsel to clients across a range of industries and has particular expertise in technology, industrial, energy, healthcare and consumer markets.
With relationships at over 50 of the top 100 private equity firms, The Lancer Group provides a range of pre-deal private equity advisory services beyond traditional executive search. These services include deal origination, diligence support and introductions to “backable” executives.
Founded in 1998, The Lancer Group is privately held and operates from offices across North America and Australia (www.thelancergroup.com).
Headquartered in Weston, Florida, BioMatrix was formed in 2015 through the merger of Matrix Health Group and BiologicTx, two nationally recognized specialty pharmacy companies that share a common business model focused on high-touch, clinically sophisticated patient-centric care management and delivering an equally compelling quality and economic value proposition to payers and providers. With a current network of 7 pharmacies, the Company is a leading provider for patients with blood disorders, organtransplants, and other chronic and acute diseases and conditions. IBioMatrix’s proprietaryDigital Health platform optimizes transplant center operations, improves care coordinationand, importantly, differentiates the Company’s strategic position and new patientacquisition. The merger of Matrix and BiologicTx was a formative step towards theCompany’s goal of developing a diversified, broadly based specialty pharmacy platform ofscale, in the fast-growing specialty pharmacy industry.
About ACON Investments
ACON Investments is a middle-market focused private equity investment firm. The firm has professionals in Washington D.C., Los Angeles, and internationally, in Mexico City, Mexico, São Paulo, Brazil and Bogotá, Colombia. The firm manages approximately $5.3 billion of assets with Limited Partners from some of the largest institutional investors in private equity, including public pension and sovereign wealth funds.
(858) 551-1001 Ext. 2860
(858) 551-1001 Ext. 2868
(858) 551-1001 Ext. 2874